Cormorant Asset Management
VC Fund
Boston, United States
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.
- Total investments:
- 249
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $75M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cormorant Asset Management invests in
Stages Cormorant Asset Management invests in
Countries Cormorant Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $16M–$102M
- Series B
- $27M–$150M
- Series C
- $30M–$146M
Investment Focus
Industry
- Biotechnology 109 (44%)
- Health Care 86 (35%)
- Medical 51 (20%)
- Therapeutics 48 (19%)
- Pharmaceutical 41 (16%)
Stage
- Series B 47 (19%)
- Series C 33 (13%)
- Series A 31 (12%)
- Post-IPO Equity 19 (8%)
- Series D 10 (4%)
Country
- United States 110 (44%)
- China 10 (4%)
- Switzerland 3 (1%)
- Denmark 2 (1%)
- Ireland 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bihua Chen
Founder, CEO & Portfolio Manager
|
Founder, CEO & Portfolio Manager | Total investments: 41 | Find email | |
|
Edward Jay Scollins
CFO and COO
|
CFO and COO | Total investments: 0 | Find email | |
| CCO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease. | $90M / Series C / Aug 11, 2026 | ||
| Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M / Post-IPO Equity / Jul 29, 2026 | ||
| Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presentingcells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology. | $50M / Post-IPO Equity / Jul 09, 2026 | ||
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | ||
| Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy Bcells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects. | $150M / Post-IPO Equity / May 04, 2026 | ||
| Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M / Post-IPO Equity / Apr 30, 2026 | ||
| Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M / Post-IPO Equity / Apr 28, 2026 | ||
| Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | ||
| Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines. | $108M / Series C / Apr 15, 2026 | ||
| Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M / Mar 02, 2026 | ||
| See all 249 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Cormorant Asset Management invest in?
Cormorant Asset Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 249 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cormorant Asset Management's check size?
Cormorant Asset Management typically joins rounds of $16M–$102M at Series A, $27M–$150M at Series B and $30M–$146M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cormorant Asset Management participates in.
How do I contact Cormorant Asset Management?
Public channels for Cormorant Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cormorant Asset Management?
The team at Cormorant Asset Management includes Bihua Chen (Founder, CEO & Portfolio Manager), Edward Jay Scollins (CFO and COO) and Nebojsa Obradovic (CCO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
